{"altmetric_id":17089702,"citation":{"altmetric_jid":"clinicaltrialsgov","authors":["University of Pennsylvania"],"first_seen_on":"2017-03-07T21:07:10+00:00","issns":[],"journal":"ClinicalTrials.gov","last_mentioned_on":1488920796,"links":["http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02651675"],"nct_id":"NCT02651675","pubdate":"2016-01-04T00:00:00+00:00","publisher":"ClinicalTrials.gov","title":"A Gene Therapy Study for Homozygous Familial Hypercholesterolemia (HoFH)","type":"clinical_trial_study_record"},"altmetric_score":{"score":25,"score_history":{"1y":25,"6m":0,"3m":0,"1m":0,"1w":0,"6d":0,"5d":0,"4d":0,"3d":0,"2d":0,"1d":0,"at":25},"context_for_score":{"all":{"total_number_of_other_articles":8320311,"mean":7.0122256031246,"rank":352789,"this_scored_higher_than_pct":95,"this_scored_higher_than":7965919,"rank_type":"exact","sample_size":8320311,"percentile":95},"similar_age_3m":{"total_number_of_other_articles":241940,"mean":13.680638309656,"rank":20395,"this_scored_higher_than_pct":91,"this_scored_higher_than":221487,"rank_type":"exact","sample_size":241940,"percentile":91},"this_journal":{"total_number_of_other_articles":24299,"mean":10.426368507696,"rank":1155,"this_scored_higher_than_pct":95,"this_scored_higher_than":23140,"rank_type":"exact","sample_size":24299,"percentile":95},"similar_age_this_journal_3m":{"total_number_of_other_articles":758,"mean":12.997019815059,"rank":38,"this_scored_higher_than_pct":94,"this_scored_higher_than":720,"rank_type":"exact","sample_size":758,"percentile":94}}},"demographics":[],"counts":{"total":{"posts_count":5},"news":{"unique_users_count":3,"unique_users":["nasdaq","yahoo_finance_usa","biz_wire_express"],"posts_count":5}},"posts":{"news":[{"title":"REGENXBIO Announces Initiation of Phase I\/II Clinical Trial of RGX-501 for the Treatment of Homozygous Familial Hypercholesterolemia","url":"http:\/\/ct.moreover.com\/?a=29819830232&p=1pl&v=1&x=VTGk4p16BdgC75yaMS8xxQ","license":"public","citation_ids":[17089702],"posted_on":"2017-03-07T21:03:00+00:00","summary":"(GLOBE NEWSWIRE) -- REGENXBIO Inc. (Nasdaq:RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV\u00ae Technology Platform, today announced that the\u2026","author":{"name":"NASDAQ","url":"http:\/\/www.nasdaq.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/839\/normal\/Screen_Shot_2016-01-27_at_11.14.52.png?1453893369"}},{"title":"REGENXBIO Announces Initiation of Phase I\/II Clinical Trial of RGX-501 for the Treatment of Homozygous Familial Hypercholesterolemia","url":"http:\/\/ct.moreover.com\/?a=29819850434&p=1pl&v=1&x=RkT9-mT9MEdebctDbAOHhA","license":"public","citation_ids":[17089702],"posted_on":"2017-03-07T21:03:00+00:00","summary":"First AAV gene therapy treatment for HoFH; interim trial update expected late 2017ROCKVILLE, Md., March 07, 2017 (GLOBE NEWSWIRE) -- REGENXBIO Inc.","author":{"name":"Yahoo! Finance USA","url":"http:\/\/finance.yahoo.com\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/620\/normal\/Screen_Shot_2016-01-07_at_10.14.50.png?1452161734"}},{"title":"REGENXBIO Announces Initiation of Phase I\/II Clinical Trial of RGX-501 for the Treatment of Homozygous Familial Hypercholesterolemia","url":"http:\/\/ct.moreover.com\/?a=29819923620&p=1pl&v=1&x=px6DQKGHsAmH5JTnrWd38w","license":"public","citation_ids":[17089702],"posted_on":"2017-03-07T21:03:00+00:00","summary":"First AAV gene therapy treatment for HoFH; interim trial update expected late 2017 ROCKVILLE, Md., March 07, 2017 (GLOBE NEWSWIRE) -- REGENXBIO Inc.","author":{"name":"Yahoo! Finance USA","url":"http:\/\/finance.yahoo.com\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/620\/normal\/Screen_Shot_2016-01-07_at_10.14.50.png?1452161734"}},{"title":"REGENXBIO Announces Initiation of Phase I\/II Clinical Trial of RGX-501 for the Treatment of Homozygous Familial Hypercholesterolemia","url":"http:\/\/ct.moreover.com\/?a=29819988950&p=1pl&v=1&x=uM3GAyyyhw7ld09cvNUL2A","license":"public","citation_ids":[17089702],"posted_on":"2017-03-07T21:03:00+00:00","summary":"First AAV gene therapy treatment for HoFH; interim trial update expected late 2017 ROCKVILLE, Md., March 07, 2017 (GLOBE NEWSWIRE) -- REGENXBIO Inc.","author":{"name":"Yahoo! Finance USA","url":"http:\/\/finance.yahoo.com\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/620\/normal\/Screen_Shot_2016-01-07_at_10.14.50.png?1452161734"}},{"title":"REGENXBIO Announces Initiation of Phase I\/II Clinical Trial of RGX-501 for the Treatment of Homozygous Familial Hypercholesterolemia","url":"http:\/\/ct.moreover.com\/?a=29819826320&p=1pl&v=1&x=RQR81J4cpyV_kd4cA3oXSQ","license":"public","citation_ids":[17089702],"posted_on":"2017-03-07T21:06:36+00:00","summary":"GlobeNewswire 2017-03-07 ROCKVILLE, Md., March 07, 2017 (GLOBE NEWSWIRE) -- REGENXBIO Inc.","author":{"name":"Biz Wire Express","url":"http:\/\/www.bizwireexpress.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/795\/normal\/Screen_Shot_2016-01-27_at_09.34.21.png?1453887297"}}]}}